June 4, 2020 -- Sweden-based Alligator Bioscience and Scandion Oncology inked an agreement to explore the antitumor efficacy of CD40 antibody mitazalimab in combination with SCO-101 and chemotherapy in preclinical tumor models.
The companies expect that SCO-101 will revert chemotherapy resistance and strengthen the antitumor effects of mitazalimab. The combination of immuno-oncology drugs with standard chemotherapy results in additive antitumor effects and more durable remissions in cancer patients.
Alligator's drug candidate mitazalimab enhances presentation of antigens released by cancer drugs and is proposed to be beneficial in combination with chemotherapy. Scandion's drug candidate SCO-101 acts by blocking resistance mechanisms in cancer cells by allowing chemotherapy to kill previously resistant cancer cells. SCO-101 would potentially restore the release of antigens and reactivate immune-oncology drugs.